指南与共识慢性肾脏病

KDOQI对美国KDIGO 2024慢性肾脏病指南的解读

KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD.
指南 / 共识 · Am J Kidney Dis · 2024-11-18

KDOQI工作组审阅了KDIGO 2024慢性肾脏病管理指南,并从美国临床实践角度提供实施建议。工作组总体同意指南中关于CKD评估、风险分层及管理(生活方式和药物)以延缓进展、处理并发症和改善心血管结局的推荐。工作组认可支持SGLT2抑制剂、GLP-1受体激动剂和非甾体盐皮质激素受体拮抗剂等新药应用的证据,并强调团队照护的重要性。

要点

  • KDOQI工作组同意KDIGO 2024指南关于CKD评估、风险分层和管理的推荐。
  • 新型药物如SGLT2抑制剂、GLP-1受体激动剂和非甾体MRA的证据支持其应用。
  • 团队照护是应对CKD负担的关键因素,实施中需关注障碍与机会。

核心结论

  • KDOQI工作组总体同意KDIGO 2024指南关于CKD评估、风险分层和管理(生活方式和药物)以延缓进展、处理并发症和改善心血管结局的推荐。
  • 工作组认可支持SGLT2抑制剂用于多种CKD病因、GLP-1受体激动剂和非甾体盐皮质激素受体拮抗剂用于合并糖尿病的2型CKD的证据基础。
  • 团队照护被工作组认定为应对日益增长的CKD负担的关键因素。

研究设计与样本

  • KDOQI召集工作组审阅KDIGO 2024慢性肾脏病管理指南。
  • 工作组审阅了KDIGO指南陈述和实践要点,并提供在美国临床实践背景下的实施视角。

主要发现

  • KDOQI工作组同意KDIGO指南中关于CKD评估、风险分层和管理以延缓进展、处理并发症和改善心血管结局的多项推荐和实践要点。
  • 工作组认可支持SGLT2抑制剂用于多种CKD病因、GLP-1受体激动剂和非甾体盐皮质激素受体拮抗剂用于合并糖尿病的2型CKD的证据。
  • 工作组评估并讨论了实施2024 KDIGO指南推荐的各种障碍和潜在机会。

临床怎么用

  • 在临床实践中可参考KDOQI对KDIGO 2024指南的解读,实施CKD评估、风险分层和管理推荐。
  • 考虑使用SGLT2抑制剂、GLP-1受体激动剂和非甾体盐皮质激素受体拮抗剂等新型药物时,应基于指南推荐和证据。
  • 推行团队照护模式以应对CKD负担,并关注实施中的障碍与机会。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Kidney Disease Outcomes Quality Initiative (KDOQI) convened a work group to review the 2024 KDIGO (Kidney Disease: Improving Global Outcomes) guideline for the management of chronic kidney disease (CKD). The KDOQI Work Group reviewed the KDIGO guideline statements and practice points and provided perspective for implementation within the context of clinical practice in the United States. In general, the KDOQI Work Group concurs with several recommendations and practice points proposed by the KDIGO guidelines regarding CKD evaluation, risk assessment, and management options (both lifestyle and medications) for slowing CKD progression, addressing CKD-related complications, and improving cardiovascular outcomes. The KDOQI Work Group acknowledges the growing evidence base to support the use of several novel agents such as sodium/glucose cotransporter 2 inhibitors for several CKD etiologies, and glucagon-like peptide 1 receptor agonists and nonsteroidal mineralocorticoid receptor antagonists for type 2 CKD in setting of diabetes. Further, KDIGO guidelines emphasize the importance of team-based care which was also recognized by the work group as a key factor to address the growing CKD burden. In this commentary, the Work Group has also assessed and discussed various barriers and potential opportunities for implementing the recommendations put forth in the 2024 KDIGO guidelines while the scientific community continues to focus on enhancing early identification of CKD and discovering newer therapies for managing kidney disease.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Navaneethan SD, Bansal N, Cavanaugh KL, et al. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD. Am J Kidney Dis. 2024. PMID: 39556063. doi:10.1053/j.ajkd.2024.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。